Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Xamoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 18/20 | 0.89 |
| ▸ | ADRB2 | P07550 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 17/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xamoterol SCHEMBL3695282 | 1.00 | ADRB2 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL1651584 | 1.00 | ADRB2 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL10584728 | 1.00 | ADRB2 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL64461 | 0.94 | ADRB1 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL30897538 | 0.94 | ADRB1 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL11533496 | 0.94 | ADRB1 (1.00) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL3702016 | 0.93 | ADRB1 (0.98) | ADRB2LMNAMEN1MAPTBLM | |
| Xamoterol SCHEMBL3697718 | 0.93 | ADRB1 (0.98) | ADRB2LMNAMEN1MAPTBLM | |
| SCHEMBL7430192 | 0.88 | ADRB2 (0.78) | ADRB2LMNAMEN1MAPTBLM | |
| SCHEMBL17028372 | 0.85 | ADRB1 (0.80) | ADRB2LMNAMEN1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0405344-B1 | 2-AMINO-1,2,3,4,-TETRAHYDRONAPHTHALENE DERIVATIVES WITH CARDIOVASCULAR ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| US-5096929-A | Inotropic agents; vasodilation | CHIESI FARMACEUTICI S.P.A. (IT) | 1992-03-17 | — | — | US | disclosed |
| EP-0405344-A2 | 2-Amino-1,2,3,4,-tetrahydronaphthalene derivatives with cardiovascular activity, process for their preparation and pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.p.A. (IT) | 1991-01-02 | — | — | EP | disclosed |
| US-4933340-A | N-(2-(RS-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYLAMINO) ETHYL)-MORPHOLINOFORMAMIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-12 | — | — | US | disclosed |
| EP-0307115-A1 | Phenol esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-03-15 | — | — | EP | disclosed |
| EP-0227339-A2 | Xamoterol for the treatment of obesity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | ADRB1 341/4885ADRB2 334/4885LMNA 1977/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | ADRB1 341/4885ADRB2 334/4885LMNA 1977/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ADRB1 3757/4885ADRB2 4274/4885LMNA 3156/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ADRB1 281/4885ADRB2 556/4885LMNA 2176/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | ADRB1 341/4885ADRB2 334/4885LMNA 1977/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ADRB1 3757/4885ADRB2 4274/4885LMNA 3156/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ADRB1 281/4885ADRB2 556/4885LMNA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.